Attached files
| file | filename |
|---|---|
| 8-K - 8-K - ALLERGAN INC | d797278d8k.htm |
 September 29, 2014
Allergan
Perspective on Valeant Pharmaceuticals
International, Inc. Sales Growth Numbers
Exhibit 99.1 |
 Important Information
Information contained in this presentation regarding Valeant Pharmaceuticals
International, Inc. (“Valeant”) is taken directly from the
information publicly disclosed by Valeant and we do not make any representations or warranties,
either express or implied, with respect to such information’s accuracy or
completeness. In addition, certain other information contained in this
presentation is based on publicly available sources as of the date of this presentation,
and while we have no reason to believe that such information is not accurate, we
can provide no such assurances with respect thereto. This presentation was
prepared with the assistance of Allergan’s independent financial
consultants and forensic accountants, Alvarez & Marsal and FTI Consulting. The
information in this presentation represents the opinions of Allergan and
investors and stockholders should make their own independent investigations
of the matters referenced in this presentation and draw their own
conclusions. 2 |
 Perspective on
Valeant’s Sales Growth Numbers •
On September 24, 2014, Valeant provided an update on
third quarter 2014 results
•
Q3 2014 growth numbers provided by Valeant should be
viewed in perspective of their Q3 2013 results
3 |
 Valeant
Quarterly Sales Growth All
data
verified
by
forensic
accountants.
All
data
from
Valeant
public
filings.
Figures
not
adjusted
for
currency
or
divestitures.
Results
for
all
periods include
divested Injectable business. Represents product sales only and is on a pro forma
basis. Bausch & Lomb Q1’12, Q2’12, Q1’13, Q2’13 from Bausch & Lomb
financial statements included in VRX 6/10/13 and 10/21/13 8Ks. Q3’13 amount
derived from subtracting other three quarters from FY13 amount per slide 150 of
Valeant 5/28/14 presentation. Q3’12 amount derived from subtracting other
three quarters from FY12 amount per Bausch & Lomb audited financial statements.
1 Based on Sept. 24, 2014 Valeant press release
YOY Growth
Q1’13
Q2’13
Q3’13
Q4’13
Q1’14
Q2’14
Q3’14¹
Total Valeant
(excluding
Generics)
1%
5%
-3%
8%
1%
7%
Total Valeant
5%
6%
-9%
4%
-1%
4%
15%
Impact of
Generics on
Total Valeant
Growth
4%
1%
-6%
-4%
-2%
-3%
4
Q3’14
growth
positively
affected
by
a
weak
Q3’13
(B&L
acquisition
on
August
6,
2013) |
 Bausch &
Lomb Quarterly Sales All
data
verified
by
forensic
accountants.
All
data
from
Valeant
public
filings.
Bausch
&
Lomb
Q1’12,
Q2’12,
Q1’13,
Q2’13
from
Bausch
&
Lomb financial
statements included in VRX 6/10/13 and 10/21/13 8Ks. Q3’13 amount derived from
subtracting other three quarters from FY13 amount per slide 150 of Valeant
5/28/14 presentation. Q3’12 amount derived from subtracting other three quarters from FY12 amount per Bausch & Lomb audited financial
statements.Figures not adjusted for currency or divestitures.
1 Based on Sept. 24, 2014 Valeant press release
2
Calculated
using
10%
Q3’14
Bausch
&
Lomb
update
as
provided
by
Valeant
on
Sept.
24,
2014
over
Q3’13
actual
sales
dollars.
5
•
Q3’14
growth
positively
affected
by
a
weak
Q3’13
(B&L
acquisition
on
August
6,
2013)
•
Q4’14 YOY growth will be against a more difficult comparable (Q4’13)
|
 Important Information
Allergan, its directors and certain of its officers and employees are participants
in solicitations of Allergan stockholders. Information regarding the names
of Allergan's directors and executive officers and their respective interests in Allergan
by security holdings or otherwise is set forth in Allergan's proxy statement for
its 2014 annual meeting of stockholders, filed with the SEC on March 26,
2014, as supplemented by the proxy information filed with the SEC on April 22, 2014.
Additional information can be found in Allergan's Annual Report on Form 10-K
for the year ended December 31, 2013, filed with the SEC on February 25,
2014 and its Quarterly Report on Form 10-Q for the quarter ended June
30, 2014, filed with the SEC on August 5, 2014. To the extent holdings of
Allergan's securities have changed since the amounts printed in the proxy
statement for the 2014 annual meeting of stockholders, such changes have been reflected on Initial
Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership
on Form 4 filed with the SEC.
These
documents
are available
free
of
charge
at
the
SEC’s
website
at
www.sec.gov.
STOCKHOLDERS
ARE
ENCOURAGED
TO
READ
ANY
ALLERGAN
PROXY
STATEMENT
(INCLUDING
ANY
SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT ALLERGAN MAY FILE WITH
THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION. Stockholders will be able to obtain, free of charge, copies of
any proxy statement and any other documents filed by Allergan
with
the
SEC
at
the
SEC's
website
at
www.sec.gov.
In
addition,
copies
will
also
be
available
at
no
charge
at
the
Investors
section
of
Allergan's
website
at
www.allergan.com.
6 |
 September 29, 2014
Allergan
Perspective
on
Valeant
Pharmaceuticals
International,
Inc. Sales Growth Numbers |